The FDA on Friday cleared the first blood test to help diagnose Alzheimer's disease, potentially paving the way for earlier detection and treatment of the dreaded neurological condition.
Why it matters: The test, developed by Fujirebio, is a more affordable alternative to PET scans or spinal taps now used to diagnose the disease, and could be incorporated into physician office visits.
Novo Nordisk CEO Lars Fruergaard Jørgensen is stepping down as the Danish drug giant faces increased competition for its weight-loss drugs and declining share price.
Why it matters: Novo has faced challenges developing next-generation obesity drugs and will see its popular but pricey GLP-1s Ozempic and Wegovy subject to the next round of Medicare drug price negotiations in the U.S.
A 9-month-old baby who was born with a rare genetic disorder is the first person to be successfully treated with personalized CRISPR gene editing therapy, scientists in Philadelphia announced on Thursday.
The big picture: This "historic medical breakthrough" could "provide a pathway for gene editing technology to be successfully adapted to treat individuals with rare diseases for whom no medical treatments are available," per a statement from the University of Pennsylvania and the Children's Hospital of Philadelphia.
Casey Means was nominated to become the new face of American public health. She's not a career doctor — but she knows how to go viral. That's the point. And the risk.
Why it matters: This is part of the Trump administration's broader strategy to prioritize messaging, allegiance and influence over expertise.
